Low dose streptozotocin is known to induce rapid destruction of pancreatic β-cells leading to impaired glucose stimulated insulin release and insulin resistance, both of which are marked features of type 2 diabetes [51]. This evidence concerns the gene INS and type 2 diabetes mellitus.